187 related articles for article (PubMed ID: 16584427)
41. [Collection of hematopoietic progenitor cells from healthy donors].
Bojanić I; Cepulić BG; Mazić S
Acta Med Croatica; 2009 Jun; 63(3):237-44. PubMed ID: 19827352
[TBL] [Abstract][Full Text] [Related]
42. Etoposide 1.0 g/m2 or 1.5 g/m2 combined with granulocyte colony-stimulating factor for mobilization of peripheral blood stem cells in patients with malignancy: efficacy and toxicity.
Li B; Yang JL; Shi YK; He XH; Han XH; Zhou SY; Liu P; Yang S; Zhang CG
Cytotherapy; 2009; 11(3):362-71. PubMed ID: 19037766
[TBL] [Abstract][Full Text] [Related]
43. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation.
Wang S; Nademanee A; Qian D; Dagis A; Park HS; Fridey J; Smith E; Snyder D; Somlo G; Stein A; Rosenthal J; Falk P; Kogut N; Palmer J; Gaal K; Kim Y; Bhatia R; Yuan S; Kay C; Weiss L; Forman S
Transfusion; 2007 Dec; 47(12):2207-16. PubMed ID: 17714420
[TBL] [Abstract][Full Text] [Related]
44. Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells.
Hicks ML; Lonial S; Langston A; Flowers C; Roback JD; Smith KJ; Mossavi Sai S; Teagarden D; Hamilton ES; Waller EK; Kaufman J
Transfusion; 2007 Apr; 47(4):629-35. PubMed ID: 17381621
[TBL] [Abstract][Full Text] [Related]
45. Influence of preapheresis clinical factors on the efficiency of CD34+ cell collection by large-volume apheresis.
Sarkodee-Adoo C; Taran I; Guo C; Buadi F; Murthy R; Cox E; Lopez R; Westphal S; Shope S; O'Connell B; Wethers L; Meisenberg B
Bone Marrow Transplant; 2003 May; 31(10):851-5. PubMed ID: 12748660
[TBL] [Abstract][Full Text] [Related]
46. Minimal number of circulating CD34+ cells to ensure successful leukapheresis and engraftment in autologous peripheral blood progenitor cell transplantation.
Pérez-Simón JA; Caballero MD; Corral M; Nieto MJ; Orfao A; Vazquez L; Amigo ML; Berges C; González M; Del Cañizo C; San Miguel JF
Transfusion; 1998 Apr; 38(4):385-91. PubMed ID: 9595022
[TBL] [Abstract][Full Text] [Related]
47. Collection and recruitment of CD34+ cells during large-volume leukapheresis.
Cull G; Ivey J; Chase P; Picciuto R; Herrmann R; Cannell P
J Hematother; 1997 Aug; 6(4):309-14. PubMed ID: 9377069
[TBL] [Abstract][Full Text] [Related]
48. DCEP chemotherapy followed by a single, fixed dose of pegylated filgrastim allows adequate stem cell mobilization in multiple myeloma patients.
Zappasodi P; Nosari AM; Astori C; Ciapanna D; Bonfichi M; Varettoni M; Mangiacavalli S; Morra E; Lazzarino M; Corso A
Transfusion; 2008 May; 48(5):857-60. PubMed ID: 18248573
[TBL] [Abstract][Full Text] [Related]
49. Mobilization of endothelial progenitor cells in patients with hematological malignancies after treatment with filgrastim and chemotherapy for autologous transplantation.
Mauro E; Rigolin GM; Fraulini C; Sofritti O; Ciccone M; De Angeli C; Castoldi G; Cuneo A
Eur J Haematol; 2007 May; 78(5):374-80. PubMed ID: 17331127
[TBL] [Abstract][Full Text] [Related]
50. A new model for predicting the timing of leukapheresis on the basis of CD34+ cell and hematopoietic progenitor cell levels.
Teng HW; Hsiao LT; Chaou SC; Gau JP; Lee TC; Shih YY; Liu CY; Hong YC; Chen MH; Chang MH; Yang YH; Chen PM
J Clin Apher; 2007; 22(4):195-203. PubMed ID: 17294459
[TBL] [Abstract][Full Text] [Related]
51. Recommendations for optimized settings of the Amicus Crescendo cell separator for the collection of CD34+ progenitor cells.
Hartwig D; Dorn I; Kirchner H; Schlenke P
Transfusion; 2004 May; 44(5):758-63. PubMed ID: 15104659
[TBL] [Abstract][Full Text] [Related]
52. Collection efficiencies of CD34+ progenitor cells and mononuclear cells in leukapheresis products quantified by flow cytometry and calculated on the basis of a new formula.
Schlenke P; Frohn C; Hennig H; Weber K; Kisro J; Saballus M; Kirchner H; Klüter H
Vox Sang; 2000; 78(4):242-9. PubMed ID: 10895098
[TBL] [Abstract][Full Text] [Related]
53. An antecedent diagnosis of refractory anemia with excess blasts has no influence on mobilization of peripheral blood stem cells and hematopoietic recovery after autologous stem cell transplantation in acute myeloid leukemia.
Viola A; Falco C; D'Elia R; D'Amico MR; Vicari L; Tambaro FP; Correale P; Laudati D; Palmieri S; Ferrara F
Eur J Haematol; 2007 Jan; 78(1):41-7. PubMed ID: 17042770
[TBL] [Abstract][Full Text] [Related]
54. Mobilization of hemopoietic stem cells with high-dose methotrexate plus granulocyte-colony-stimulating factor in patients with primary central nervous system lymphoma.
Kiefer T; Krüger WH; Montemurro M; Schüler F; Hirt C; Pasold R; Niederwieser D; Schwenke M; Dölken G
Transfusion; 2008 Dec; 48(12):2624-8. PubMed ID: 18801020
[TBL] [Abstract][Full Text] [Related]
55. A randomized comparison of peripheral blood hematopoietic progenitor cell level of 5/mm3 versus 50/mm3 as a surrogate marker to initiate efficient autologous blood stem cell collection.
Kim MK; Kim S; Jang G; Lee SS; Sym SJ; Lee DH; Kim SW; Jang S; Park CJ; Chi HS; Huh J; Suh C
J Clin Apher; 2007; 22(5):277-82. PubMed ID: 17880017
[TBL] [Abstract][Full Text] [Related]
56. Large-volume leukapheresis for peripheral blood progenitor cell collection in low body weight pediatric patients: a single center experience.
Cecyn KZ; Seber A; Ginani VC; Gonçalves AV; Caram EM; Oguro T; Oliveira OM; Carvalho MM; Bordin JO
Transfus Apher Sci; 2005 Jun; 32(3):269-74. PubMed ID: 15908275
[TBL] [Abstract][Full Text] [Related]
57. Single-dose pegfilgrastim is comparable to daily filgrastim in mobilizing peripheral blood stem cells: a case-matched study in patients with lymphoproliferative malignancies.
Putkonen M; Rauhala A; Pelliniemi TT; Remes K
Ann Hematol; 2009 Jul; 88(7):673-80. PubMed ID: 19139894
[TBL] [Abstract][Full Text] [Related]
58. Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor.
Bruns I; Steidl U; Fischer JC; Czibere A; Kobbe G; Raschke S; Singh R; Fenk R; Rosskopf M; Pechtel S; von Haeseler A; Wernet P; Tenen DG; Haas R; Kronenwett R
Haematologica; 2008 Mar; 93(3):347-55. PubMed ID: 18268278
[TBL] [Abstract][Full Text] [Related]
59. A rationale for positive selection of peripheral blood stem cells in multiple myeloma: highly purified CD34+ cell fractions of leukapheresis products do not contain malignant cells.
Cremer FW; Kiel K; Sucker C; Wacker J; Atzberger A; Haas R; Goldschmidt H; Moos M
Leukemia; 1997 Dec; 11 Suppl 5():S41-6. PubMed ID: 9436938
[TBL] [Abstract][Full Text] [Related]
60. The CD34+ cell concentration in peripheral blood predicts CD34+ cell yield in the leukapheresis product.
Hollingsworth KL; Zimmerman TM; Karrison T; Oliver A; Williams SF
Cytotherapy; 1999; 1(2):141-6. PubMed ID: 19746591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
